The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agendia; AstraZeneca; Clovis Oncology; Eisai; Genomic Health; Immunomedics/Gilead; Lilly O.; MSD; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Seagen; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Eisai; Genomic Health; Gilead Sciences; Pfizer; Tesaro/GSK; Vaccibody (Inst)
Speakers' Bureau - Amgen; Palleos
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Frederik Marmé
No Relationships to Disclose
 
Javier Cortés
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung Bioepis
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; Erytech Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; Zymeworks
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
Other Relationship - ARIAD; AstraZeneca; Baxalta; Bayer; Eisai; Guardant Health; Merck Sharp & Dohme; Pfizer; Piqur; Puma C; Queen Mary University of London; Roche; Roche
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Delphine Loirat
Honoraria - AstraZeneca; Gilead Sciences; Gilead Sciences; Lilly; MSD
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Gilead Sciences; Immunomedics; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; MSD; Pfizer; Roche
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sandoz-Novartis; Seagen; Stemline Therapeutics; Viatris
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Eva M Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Florence Dalenc
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Novartis; Pfizer
 
Patricia Gómez Pardo
No Relationships to Disclose
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Rosemary Delaney
Employment - Gilead Sciences
 
Theresa Valdez
Stock and Other Ownership Interests - Gilead Sciences
 
Oh Kyu Yoon
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Hao Wang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Wendy Verret
Employment - Gilead Sciences; Roche/Genentech
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck